Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Antibody discovery could explain why so many group A strep vaccines have failed

Researchers at Lund University in Sweden have discovered an antibody with the potential to protect against Strep A infection, as well as a rare form of antibody binding, that leads to an effective immune response against bacteria.

12 Dec 2022

COVID-19 vaccination temporarily alters heart rate variability

HRV parameters after COVID-19 vaccination show significant short-term changes that may persist for up to three days until ultimately returning to baseline.

12 Dec 2022

Detection of unreported infections based on SARS-CoV-2 antibody seroprevalence

Researchers analyzed data from SARS-CoV-2 seroprevalence studies to elucidate the nationwide temporal trends of COVID-19 prevalence.

12 Dec 2022

Immunogenicity of SARS-CoV-2 antibody response in immune naïve children and adults

Researchers compare the contribution of antibodies against the SARS-CoV-2 receptor binding domain in vaccinated and naturally infected adults and children.

12 Dec 2022

XBB Omicron variant evades vaccine-induced immunity

A new study published in The Lancet Microbe examines the immune evasion characteristics of the Omicron XBB subvariant.

12 Dec 2022

Novel drug shows early potential in combating multiple myeloma

A first-of-its-kind drug known as modakafusp alfa has shown early potential in combating multiple myeloma, a form of bone marrow cancer, in a study presented by researchers from the University of Pennsylvania's Abramson Cancer Center at the 2022 American Society of Hematology Annual Meeting (Abstract 565).

12 Dec 2022

Novel monoclonal antibody therapy shows promising results in patients with moderate to severe atopic dermatitis

Patients with moderate to severe atopic dermatitis who participated in a clinical trial of rocatinlimab - a novel, patient-tailored monoclonal antibody therapy - showed promising results both while taking the drug and up to 20 weeks after the therapy was stopped, Mount Sinai researchers reported in The Lancet.

12 Dec 2022

Three-drug combination highly effective in patients with high-risk forms of chronic lymphocytic leukemia

A three-drug combination that sent chronic lymphocytic leukemia (CLL) into deep remissions in a broad group of patients in a clinical trial is highly effective in patients with high-risk forms of the disease, a new, phase 2 clinical trial led by Dana-Farber Cancer Institute investigators indicates.

12 Dec 2022

Study shows emerging Omicron sublineages efficiently evade neutralization independent of immunization history

Researchers evaluated the effects of hybrid immunity and booster vaccination on Omicron sublineages.

12 Dec 2022

Off-the-shelf immunotherapy could offer new hope for patients with hard-to-treat multiple myeloma

A new therapy that makes the immune system kill bone marrow cancer cells was successful in as many as 73 percent of patients in two clinical trials, according to researchers from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai.

12 Dec 2022

Intranasal recombinant MVA-based vaccines effective against SARS-CoV-2 variants in mice

Researchers construct a recombinant host-range restricted vaccinia virus Ankara (rMVAs) expressing the spike proteins of several SARS-CoV-2 variants.

11 Dec 2022

Trial establishes the clinical utility of circulating tumor cell count as biomarker in breast cancer care

The use of circulating tumor cell (CTC) count to guide the choice between chemotherapy and endocrine therapy as first-line therapy for patients with metastatic, estrogen receptor (ER)-positive/HER2-negative breast cancer provided overall survival benefit, compared with physician's choice of treatment, according to data from the STIC CTC trial presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.

8 Dec 2022

Multi-stage HIV vaccine regimen shows promising results in Phase 1 clinical trial

The George Washington University Vaccine Research Unit in partnership with Scripps Research, IAVI, Fred Hutchinson Cancer Center (FHCC) and the National Institutes of Health, National Institute of Allergy and Infectious Diseases Vaccine Research Center published the results of their Phase 1 Clinical Trial in Science.

8 Dec 2022

Antibodies against gentamicin associated with increased risk of type 1 diabetes in children

Antibodies produced against the commonly used antibiotic, gentamicin, appear to increase the risk of type 1 diabetes in children already genetically at risk, scientists say.

8 Dec 2022

Exploring a variant-adapted SARS-CoV-2 recombinant protein vaccine

Researchers assessed the immunogenicity of a variant-adapted severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant protein vaccine boosted with an AS03 adjuvant.

8 Dec 2022

Booster COVID-19 mRNA vaccinations marginally increase the durability of neutralizing antibody responses

Researchers investigated the immunological mechanisms behind the decreasing efficacy of COVID-19 vaccines by evaluating the durability and magnitude of neutralizing antibodies and memory B and T cell responses to booster doses of mRNA COVID-19 vaccine.

8 Dec 2022

Scientists develop new receptor “decoy” drug that potently neutralizes SARS-CoV-2 variants

Scientists at Dana-Farber Cancer Institute have developed a drug that potently neutralizes SARS-CoV-2, the COVID-19 coronavirus, and is equally effective against the Omicron variant and every other tested variant.

7 Dec 2022

T-DXd leads to longer overall survival in HER2-positive metastatic breast cancer patients than T-DM1

Second-line treatment with trastuzumab deruxtecan (T-DXd) led to significantly longer overall survival compared with trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer, according to updated results from the DESTINY-Breast03 phase III clinical trial presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.

7 Dec 2022

T-DXd shows high efficacy in HER2-positive breast cancer patients previously treated with T-DM1

Compared with capecitabine-based regimens, trastuzumab deruxtecan (T-DXd) led to higher response rates and longer survival in the third-line setting for patients with HER2-positive metastatic breast cancer previously treated with trastuzumab emtansine (T-DM1), according to results from the phase III DESTINY-Breast02 trial presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.

7 Dec 2022

Researchers share results of MVA-BN-respiratory syncytial virus vaccine human challenge trial

Researchers reported the immunogenicity, efficacy, and safety of the MVA-BN (modified vaccinia Ankara-Bavarian Nordic)-RSV (respiratory syncytial virus) vaccine against RSV-A (RSV subtype A) Memphis 37b strain in a human challenge trial.

7 Dec 2022

Antibody News and Research

Further Reading

Antibody discovery could explain why so many group A strep vaccines have failed

COVID-19 vaccination temporarily alters heart rate variability

Detection of unreported infections based on SARS-CoV-2 antibody seroprevalence

Immunogenicity of SARS-CoV-2 antibody response in immune naïve children and adults

XBB Omicron variant evades vaccine-induced immunity

Novel drug shows early potential in combating multiple myeloma

Novel monoclonal antibody therapy shows promising results in patients with moderate to severe atopic dermatitis

Three-drug combination highly effective in patients with high-risk forms of chronic lymphocytic leukemia

Study shows emerging Omicron sublineages efficiently evade neutralization independent of immunization history

Off-the-shelf immunotherapy could offer new hope for patients with hard-to-treat multiple myeloma

Intranasal recombinant MVA-based vaccines effective against SARS-CoV-2 variants in mice

Trial establishes the clinical utility of circulating tumor cell count as biomarker in breast cancer care

Multi-stage HIV vaccine regimen shows promising results in Phase 1 clinical trial

Antibodies against gentamicin associated with increased risk of type 1 diabetes in children

Exploring a variant-adapted SARS-CoV-2 recombinant protein vaccine

Booster COVID-19 mRNA vaccinations marginally increase the durability of neutralizing antibody responses

Scientists develop new receptor “decoy” drug that potently neutralizes SARS-CoV-2 variants

T-DXd leads to longer overall survival in HER2-positive metastatic breast cancer patients than T-DM1

T-DXd shows high efficacy in HER2-positive breast cancer patients previously treated with T-DM1

Researchers share results of MVA-BN-respiratory syncytial virus vaccine human challenge trial

Accelerating therapeutic antibody discovery and development eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo